Currently available medications could be enough to end the HIV epidemic in the United States, provided people can access and ...

A new analysis finds that generic lenacapavir, a twice-yearly HIV preventive treatment, could be mass produced for just $25 ...

Dr Joel Steingo of TB HIV Care says Lenacapavir could be a breakthrough in reducing infections, especially at a time when ...

Now, the fight against HIV/AIDS is not just about governments and global health organisations anymore; it is a deeply personal one. And it is all about the choices you make, the conversations you have ...

It will bring support services to Bangor, while another program is expanding HIV and AIDS services to all but two counties in ...

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

"Somebody is trusting their family member or their loved one into your hands to be a caregiver to them,” says Judi Lacinak, NP. “That's a privilege that we can't take lightly.” ...

SHELTON, CONNECTICUT / ACCESS Newswire / October 15, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), reports ...

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 ...

The understated green and white box labeled Aspirina that started rolling out in select Walmart and Walgreens locations this ...

Ritshidze, South Africa's powerhouse community-led healthcare monitor, is on the brink of shutting down. Experts warn its collapse could unravel years of progress in our clinics - just as worrying new ...

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused ...